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Patients with rheumatic diseases have an increased risk of mortality by cardiovascular events. In fact, several rheumatic diseases
such as rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, and ankylosing spondylitis are associated with a
higher prevalence of cardiovascular diseases (CVDs). Although traditional cardiovascular risk factors have been involved in
the pathogenesis of cardiovascular diseases in rheumatic patients, these alterations do not completely explain the enhanced
cardiovascular risk in this population. Obesity and its pathologic alteration of fat mass and dysfunction, due to an altered pattern
of secretion of proinflammatory adipokines, could be one of the links between cardiovascular and rheumatic diseases. Indeed,
the incidence of CVDs is augmented in obese individuals with rheumatic disorders. Thus, in this paper we explore in detail the
relationships among adipokines, rheumatic diseases, and cardiovascular complications by giving to the reader a holistic vision and
several suggestions for future perspectives and potential clinical implications.
1. Introduction
Patients with rheumatic diseases have an increased risk of
mortality and fatal cardiovascular events. Several rheumatic
diseases including rheumatoid arthritis (RA), osteoarthritis
(OA), systemic lupus erythematosus (SLE), and ankylosing
spondylitis (AS) have been associated with higher prevalence
of cardiovascular diseases (CVDs) [1]. For instance, CVDs
are responsible for almost 50% excess of mortality in patients
with RA [2, 3].
Classic risk factors such as obesity and the related
metabolic syndrome, presented in patients with rheumatic
diseases, might explain the increased risk of CVDs occurred
in rheumatic disorders [4]. In fact, there are reports showing
a major prevalence of metabolic syndrome in lupus patients
compared to healthy controls, and a higher risk of CVDs
in these patients was also reported [5, 6]. Moreover, it has
been reported that there is a considerably higher prevalence
to develop metabolic syndrome and CVDs in AS patients [7].
White adipose tissue is described as an endocrine organ,
which secrete a wide variety of factors called adipokines,
which have multiple functions. At present, it is well known
that adipokines play relevant roles in the pathophysiology
of rheumatic diseases and CVDs [8, 9]. To note, visceral
fat accumulation associated with adipokine dysregulation
affects both atherosclerotic plaque development and plaque
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disruption [10, 11]. Clearly, when the advanced plaque
becomes unstable, ruptures can occur, establishing an acute
coronary syndrome that is aggravated by the adipokine-
induced prothrombotic and inflammatory state, which can
further worsen syndromes.
Here, we present an updated review based on the func-
tion played by four adipose tissue-derived factors (leptin,
adiponectin, visfatin, and resistin) in atherosclerosis and
different rheumatic diseases.
2. Leptin
Leptin is a 16 kDa nonglycosylated hormone encoded by
the gene ob, the murine homologue of the human gen LEP
[12]. It belongs to class I cytokine superfamily, consisting
of a bundle of four α-helices. Leptin is mainly produced
by adipocytes and circulating levels are correlated with
WAT (white adipose tissue) mass. It decreases food intake
and increases energy consumption by acting on specific
hypothalamic nuclei, where leptin induces anorexigenic fac-
tors as cocaine amphetamine-related transcript (CART) and
suppressing orexigenic neuropeptides such as neuropeptide
Y (NPY) [13]. Leptin levels are mostly dependent on the
amount of body fat, but its synthesis is also regulated by
inflammatory mediators [14]. Leptin exerts its biological
actions through the activation of its cognate receptors, which
are encoded by the diabetes gene (db) and belong to the
class I cytokine receptor superfamily. There are six different
isoforms of leptin receptors, but only the long isoform
is functional (Ob-Rb). Several tissues produce leptin and
express its receptors, including those of the cardiovascular
system such as blood vessels and cardiomyocytes [15]. Leptin
gene expression is mainly regulated by food intake, energy
status, hormones, and also by inflammatory mediators [8,
16]. Genetic deficiency in the gene encoding for leptin or its
receptors provokes severe obesity and diabetes mellitus.
3. Leptin and Atherosclerosis
Leptin is associated with cardiovascular diseases (CVD)
(Figure 1), In fact, elevated serum concentrations of this
adipokine are related with myocardial infarction and stroke
independently of traditional cardiovascular risk factors
[17]. Moreover, it has been proposed that leptin plays a
pathogenic role in atheromatous plaques, due to its positive
association with C-reactive protein (CRP) and soluble
IL-6 receptor (sIL-6R) [18], two inflammatory mediators
involved in the pathogenesis of atherosclerosis [19, 20].
The proatherogenic actions of leptin are supported by
several experimental observations demonstrating that this
adipokine induces hypertrophy of vascular smooth muscle
cells [21] and the production of matrix metalloproteinase
2 (MMP-2) [22]. The latter develops main actions in
plaque rupture [23]. Also, leptin could stimulate vascular
remodeling by promoting profibrotic cytokines production
[24]. Apart from this, leptin increases the secretion of
proatherogenic lipoprotein lipase by cultured human and
murine macrophages [25], enhances platelet aggregation
[26, 27], and induces C-reactive protein (CRP) expression in
human coronary artery endothelial cells [28].
It has been described that leptin induces caveolin-1
expression in endothelial cells [29]. Caveolin-1 plays a rel-
evant regulatory role in the development of atherosclerosis,
promoting the transcytosis of LDL to the subendothelial
space, and inhibiting eNOS function [30, 31]. This study
represents a novel mechanism through which hyperleptine-
mia contributes to the development of atherosclerosis.
Recently, it has been reported that leptin was able to increase
plasminogen activator inhibitor-1 (PAI-1) expression in
human coronary artery endothelial cells [32]. PAI-1 plays
an important role in the development and progression
of atherosclerosis [33, 34], with its deficiency described
to protect being against atherosclerosis progression [35].
Indeed, in human atherosclerotic arteries, PAI-1 production
and enhanced expression appear to be directly related with
the degree of atherosclerosis [36].
4. Leptin and Rheumatic Diseases
In addition to its well-known actions on immune system,
leptin has also been associated with rheumatic diseases due
to its ability to modulate bone and cartilage metabolism
[37, 38].
Leptin plays main actions in certain autoimmune dis-
eases such as rheumatoid arthritis (RA). This idea is
supported by several in vitro and in vivo studies. Serum
leptin levels were increased in RA patients compared to
healthy controls [39, 40]; however, other studies reported
unchanged levels [41]. Moreover, several authors suggested
that a correlation between the RA disease activity and
leptin levels might exist [42–44]. To note, synovial/serum
leptin ratio was correlated with disease duration and erosion
parameters in RA patients [45], whereas other authors did
not found any correlation between leptin levels and disease
activity [46]. In patients undergoing anti-TNF-α therapy
because of severe diseases refractory to conventional therapy,
there was a positive correlation between body mass index
of RA patients and serum level of leptin [46]. Interestingly,
in these patients there was a correlation between leptin
levels and VCAM-1 [46]. This is of potential irrelevance
as biomarkers of endothelial dysfunction endothelial cell
activation have been found elevated in patients with RA
and anti-TNF blockade improved endothelial dysfunction
[47] and also yielded a decrease of the levels of some of
these endothelial cell activation biomarkers [48]. Regrettably,
although different studies have confirmed the influence of
gene polymorphisms, located in inside and outside the
MHC region, in the increased risk of endothelial dysfunction
and cardiovascular events observed in patients with RA
[49–51], leptin-LEP polymorphisms do not seem to be a
genetic risk factor for disease susceptibility or clinically
evident cardiovascular disease and subclinical atherosclerosis
in patients with RA [52].
Low leptin levels, related with food restriction, have been
linked to CD4+ lymphocyte hyporeactivity and increased
interleukin-4 secretion [53]. Leptin was involved in RA-
induced hypoandrogenicity, due to the fact that leptin levels
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Figure 1: Schematic representation of the involvement of leptin, adiponectin, resistin, and visfatin in atherosclerosis.
were negatively correlated to androstenedione [54]. Then,
since leptin acts as a proinflammatory factor and androgens
are commonly considered as anti-inflammatory agents, the
preponderance of leptin and hypoandrogenicity may help
to perpetuate chronic rheumatic diseases such as RA. In
addition, TNF-α blockers such as infliximab or adalimumab
did not modify serum leptin levels [46, 54, 55]. Several
studies carried out in arthritis animal models, as well as
in vitro studies, support the involvement of leptin in RA [56].
Leptin stimulation increases IL-8 production in RA
synovial fibroblasts via leptin receptor/JAK2/STAT3 pathway
[57]. However, the effects of leptin in RA are not only related
to articular tissues. Leptin also modulates the activity of
multiple immune cells, including regulatory T cells, which
are potent inhibitors of autoimmunity [58]. The ability of
leptin to induce regulatory T cells anergy and T-cell receptor
hyporesponsiveness has gained much interest since altered
functioning of this cell type was described in RA [59].
Leptin has also been related with osteoarthritis (OA)
and cartilage metabolism. It is known that chondrocytes
from human OA cartilage produce much more leptin than
chondrocytes from normal cartilage [60]. Moreover, leptin
was found in synovial fluid from OA-affected joints [60, 61].
In fact, the expression pattern of leptin was related to the
grade of cartilage destruction [60] and with the severity of
the disease, with the highest levels of leptin in being the
advanced stages of the disease [62, 63].
Recently it has been reported that extreme obesity due
to the impaired leptin signalling induces alterations in
subchondral bone morphology but without increasing the
incidence of OA [64]. These results suggest that obesity, per
se, is not sufficient to induce OA, leptin being necessary
in the development and progression of OA associated with
obesity. In vitro experiments also pointed a role of leptin
in OA. Leptin increases IL-8 production by OA synovial
fibroblasts and chondrocytes [57, 65]. In human cultured
chondrocytes, leptin synergizes with IL-1 and interferon-γ
in the synthesis of nitric oxide [38, 66]. In addition, this
adipokine enhances MMP-9, MMP-13, prostaglandin E2 and
IL-6 production in human chondrocytes [63, 67]. Leptin has
also been related with bone metabolism. Actually it has been
suggested that abnormal leptin production by OA osteoblasts
could be responsible for an altered osteoblast function in OA
[68].
Regarding the role of leptin in systemic lupus erythema-
tous (SLE), some contradictory data exists. Nowadays, most
of the studies suggest a role for leptin in this disease. Several
authors found higher leptin levels in SLE patients compared
with healthy controls, even after BMI correction [69–73].
Interestingly, in some of these studies, the hyperleptinemia
was associated with cardiovascular diseases and with several
features of the metabolic syndrome [72, 73]. Indeed, using a
lupus animal model, it was determined that leptin enhanced
the proinflammatory high-density lipoproteins scores and
atherosclerosis induced by a high-fat diet [74], indicating
that factors related with metabolic syndrome can accelerate
the disease and its cardiovascular complications. On the
other hand, other groups have described lower or unchanged
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Figure 2: Schematic representation of leptin implication in several rheumatic diseases.
circulating leptin levels in SLE patients compared to healthy
control [75, 76].
The role of leptin in ankylosing spondylitis (AS) is
still unclear and the data available are almost limited. For
instance, certain studies have not found any correlation
between serum leptin concentrations and markers of disease
activity [77, 78]. However, other authors determined an asso-
ciation among serum leptin levels, CRP, IL-6, and markers of
disease activity [79, 80]. In addition, it has been also reported
that peripheral blood mononuclear cells (PBMCs) from AS
patients express higher amounts of leptin compared with
PBMCs from controls [81], and exogenous administration
of leptin exacerbates the production of proinflammatory
cytokines in PBMCs from AS patients compared with those
from controls [81] (Figure 2).
5. Adiponectin
Adiponectin, also known as GBP28, apM1, Acrp30, or
AdipoQ, is a 244-residue protein with structural homology
to types VIII and X collagen and complement factor C1q that
is prevalently synthesized by adipose tissue. Adiponectin cir-
culates in the blood in large amounts and constitutes approx-
imately 0.01% of the total plasma proteins and it is secreted
from adipocytes as different molecular forms (trimers, hex-
amers, and also 12–18-monomer forms) [82, 83]. It increases
fatty acid oxidation and reduces the synthesis of glucose in
the liver and other tissues [82]. Ablation of the adiponectin
gene has no dramatic effect on knockout mice on a normal
diet, but when placed on a high-fat/sucrose diet, animals
develop severe insulin resistance and exhibit lipid accumula-
tion inmuscles [84]. Circulating adiponectin levels tend to be
low in morbidly obese patients and increase with weight loss
and with the use of thiazolidinediones (insulin-sensitizing
drugs) which enhance sensitivity to insulin [82, 85].
Adiponectin acts via two receptors, one (AdipoR1) found
predominantly in skeletal muscle and the other (AdipoR2) in
liver. Transduction of the adiponectin signal by AdipoR1 and
AdipoR2 involves the activation of AMPK, PPAR-α, PPAR-
γ, and other signalling molecules [82]. To note, targeted
disruption of AdipoR1 and AdipoR2 causes abrogation of
adiponectin binding and all its metabolic actions [86].
The gene that codes for human adiponectin is located on
chromosome 3q27, a locus linked with susceptibility to
diabetes and cardiovascular diseases [87].
6. Adiponectin and Atherosclerosis
Unlike most other adipokines, plasma levels of adiponectin
are decreased in obesity and related pathologies, includ-
ing type 2 diabetes and cardiovascular diseases [88].
Adiponectin possesses multiple healthy effects on obesity-
related metabolic complications, dyslipidaemia, nonalco-
holic fatty liver disease, and several types of cancers [89]. It
has been suggested that hypoadiponectinemia is an indepen-
dent risk factor for hypertension [90] and has a detrimental
effect on aortic stiffness [91]. Furthermore, subjects carrying
the genetic variants that are related to lower plasma levels
of adiponectin have a higher risk of hypertension [92,
93]. Several studies have shown that dyslipidemia is also
associated with low circulating levels of adiponectin, even
in the absence of other metabolic syndrome risk factors
[94]. Hypoadiponectinemia has been linked to inflammatory
atherosclerosis, suggesting that normal adiponectin levels are
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required to maintain a noninflammatory phenotype on the
vascular wall [8].
Adiponectin might regulate many steps in the athero-
genic process, such as antiapoptotic actions on endothelial
cells and angiogenic effects on the vasculature [95]. Anti-
atherosclerotic effects of adiponectin were exerted through
multiple actions on almost each vascular cell type, such as
cardiomyocyte endothelial cell and endothelial progenitor
cell. Particularly, adiponectin inhibits neointimal formation
by suppressing proliferation and migration of vascular
smooth muscle cells [96–98], blocks inflammation and
foam cell formation from macrophages [99, 100] and
stimulates the production of the anti-inflammatory cytokine
IL-10 and of interleukin 1 receptor antagonist (IL1Ra) by
macrophages [101]. Adiponectin also was able to inhibit
the production of reactive oxygen species (ROS) in cultured
endothelial cells [102–104]. In addition to its effects on the
vasculature, several studies in vitro and in vivo demonstrated
that adiponectin acts directly on cardiomyocytes to protect
the heart from ischaemic injury, hypertrophy, cardiomy-
opathy and systolic dysfunction [105]. In particular, the
cardioprotective effects of adiponectin are attributed to its
ability in suppressing apoptosis, oxidative/nitrative stress,
and inflammation in cardiomyocytes [106]. Also, high
plasma adiponectin levels are associated with a lower risk
of myocardial infarction in men [107], a reduced coronary
heart disease risk in patients with diabetesmellitus [108], and
a lower risk of acute coronary syndrome [109] (Figure 1).
7. Adiponectin and Rheumatic Diseases
In contrast to its previously described protective role in
cardiovascular diseases and obesity, there are multiple evi-
dence that adiponectin acts as a proinflammatory factor
in joints and it could be involved in matrix degradation.
Adiponectin levels have been found to be higher in RA
patients than in healthy controls [39, 110–114]. Recently,
it has been reported that adiponectin and adiponectin
receptor-1 expression are higher in synovial fluids and the
synovial tissues of RA patients compared with controls,
confirming the correlation of circulating adiponectin levels
with the severity of RA [115]. In RA patients undergoing
anti-TNF infliximab therapy because of severe disease, high-
grade inflammation was independently and negatively cor-
related with circulating adiponectin concentrations, whereas
low adiponectin levels clustered with metabolic syndrome
features such as dyslipidemia and high plasma glucose levels
that have been reported to contribute to atherogenesis in
RA [116]. However, the interaction of high-grade inflamma-
tion with low circulating adiponectin concentrations does
not likely to be TNF-α mediated in RA [116]. Also, no
association between adiponectin and carotid intima-media
wall thickness, a surrogate marker of cardiovascular events
in RA [117], was observed in patients with RA [118]. In
keeping with these negative results, no associations between
functional adiponectin-ADIPOQ rs266729 and ADIPOQ
rs1501299 polymorphisms and cardiovascular disease were
found in patients with RA [119].
Several studies supported the catabolic role for adi-
ponectin. It has been reported that adiponectin is able
to stimulate the production of PGE2, IL-6, IL-8, vascular
endothelial growth factor, and MMP-1 and MMP-13 in RA
synovial fibroblasts [62, 120–122]. In addition, in cultured
human chondrocytes and synovial fibroblasts, adiponectin
also induces the production of NO, IL-6, MMP-3, MMP-
9, monocyte chemotactic protein 1 (MCP-1), and IL-8 [65,
123–125]. Adiponectin has a similar behaviour in other
cell types also involved in the RA, such as lymphocytes
and human macrovascular endothelial cells. This adipokine
promotes inflammation through increased TNF-α, IL-6, IL-
8, and RANTES secretion by human primary lymphocytes.
Moreover, it induces IL-6, IL-8, MCP-1, and RANTES secre-
tion by human macrovascular endothelial cells [126, 127].
Concerning the role of adiponectin in SLE, several
studies have showed elevated levels of this adipokine in
SLE patients [70, 73, 75]. Nevertheless, other authors did
not find any difference in adiponectin levels between SLE
patients and controls [72, 128]. However, the same authors
find a positive correlation of leptin with vascular stiffness
parameters whereas adiponectin inversely correlates [129].
In the study by Rovin et al. [130], the authors showed that
serum adiponectin levels are higher in patients with renal
SLE than in healthy controls and in patients with nonrenal
SLE. In addition, lower levels of adiponectin were presented
in SLE patients with insulin resistance (IR) compared to SLE
subjects without IR [70]. It also has reported that mice with
experimental lupus, that lack adiponectin, develop more
severe disease than wild-type mice, suggesting the involve-
ment of adiponectin in regulating disease activity [131].
In addition, very recently, McMahon and colleagues
have demonstrated that leptin levels confer increased risk
of atherosclerosis in women with systemic lupus erythe-
matosus and that there is no significant association between
adiponectin and atherosclerotic plaques in SLE [132].
Little is known about the role of adiponectin in other
rheumatic diseases, such as AS and Sjo¨gren’s syndrome.
However, it has reported that serum adiponectin levels are
not different between AS patients and healthy controls [78].
Regarding the Sjo¨gren’s syndrome, it has been described that
adiponectin is expressed in salivary gland epithelial cells, and
this expression is higher in patients with Sjo¨gren’s syndrome
[133]. Moreover, the same group was demonstrated that
adiponectin is able to protect salivary gland epithelial
cells from spontaneous and INF-γ-induced apoptosis [134]
(Figure 3).
8. Visfatin
Visfatin, also called PBEF (pre-B-cell colony-enhancing fac-
tor), and Nampt (nicotinamide phosphoribosyltransferase),
is a protein of approximately 471 amino acids and 52 kDa
[135]. It is a hormone that originally was discovered in liver,
bone marrow, and muscle, but it is also secreted by visceral
fat [135, 136].
It has been reported that visfatin is increased in obesity.
Moreover, leucocytes from obese patients produce higher
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Figure 3: Schematic representation of adiponectin implication in several rheumatic diseases.
amounts of visfatin compared with lean subjects, and specif-
ically, granulocytes and monocytes are the major producing
cells [137, 138].Macrophages have been described as a source
for visfatin production too [139].
It is supposed that visfatin has insulin mimetic prop-
erties; however, the role of this adipokine in glucose
metabolism is still unclear [136, 140]. Visfatin is upregulated
in models of acute injury and sepsis [141], and its synthesis
is regulated by other factors such as glucocorticoids, TNF-
α, IL-6, and growth hormone (GH). Moreover, visfatin has
been shown to induce chemotaxis and the production of IL-
1β, TNF-α, and IL-6 in lymphocytes [138].
9. Visfatin and Atherosclerosis
The role played by visfatin in atherosclerosis is still confused,
but some studies recognize the involvement of this adipokine
in atherosclerotic processes (Figure 1). Serum visfatin con-
centrations were increased in metabolic syndrome patients
with atherosclerotic plaques compared with those without
carotid atherosclerosis [142]. Moreover, visfatin expression
was found to be increased in symptomatic plaques, while
asymptomatic plaques presented lower visfatin expression
[143]. Recently, it has been described that visfatin pericoro-
nary fat expression was positively correlated with coronary
atherosclerosis [144], in addition CRP and the atherogenic
small dense low-density lipoprotein subclasses (sdLDL-C)
levels were increased in individuals with higher visfatin levels
[145]. All of these data suggest that visfatin develops certain
actions in the progression of atherosclerosis, probably related
to the fact that visfatin acts as an inflammatory mediator.
In vitro experiments support a proinflammatory role
of visfatin. This adipokine induces MCP-1 expression in
human endothelial cells via NF-κB and PI3Kinase [146].
In line with this, macrophage foam cells from coronary
atherosclerotic lesions produce visfatin, and this is able to
enhance inflammatory factors synthesis such as IL-8, TNF-α,
or MMP-9 in the monocytic cell line THP-1 and in PBMCs
[143]. These results indicate strong proinflammatory effects
of visfatin, which could be related with atherogenesis and
plaque destabilization.
Another study reveals that visfatin could improve endo-
thelial function by increasing eNOS expression [147].
10. Visfatin and Rheumatic Diseases
Serum visfatin levels were also increased in RA patients com-
pared with healthy controls [39, 112, 148]. This adipokine
has important proinflammatory and catabolic roles in RA
pathogenesis, and it is now being intensively studied as a
potential target in this illness. In fact, serum and synovial
visfatin concentrations were associated with the degree of
inflammation, clinical disease activity, and with increased
radiographic joint damage [112, 149, 150]. Although in a
study that included RA patients with severe disease under-
going anti-TNF-α infliximab therapy, visfatin levels were
not associated with inflammation or metabolic syndrome
and infliximab infusion did not show significant changes in
visfatin levels [151], another study showed that prolonged
anti- TNF-α treatment may reduce visfatin levels [151, 152].
Brentano et al. reported an interesting study, in which high
levels of visfatin were observed in the synovial lining layer
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and at sites of cartilage loss [149]. In addition, the authors
demonstrate that visfatin induced IL-6, IL-8, MMP-1, and
MMP-3 production in RA synovial fibroblasts as well as IL-
6 and TNF-α in monocytes. Notably, visfatin knockdown in
RA synovial fibroblasts significantly reduced the synthesis of
IL-6, IL-8, MMP-1, and MMP-3 [149].
Other authors identified visfatin as a key component of
the inflammatory processes leading to arthritis, because vis-
fatin inhibition significantly reduced inflammation, cartilage
damage, and the severity of arthritis in a collagen-induced
arthritis animal model [153]. Moreover, the inhibition of
this adipokine reduced the circulating levels of TNF-α
[153]. Anyway, the mechanisms by which visfatin exerts its
proinflammatory and catabolic functions in the arthritic
joint are not well understood, therefore, the use of visfatin
as a therapeutic target needs to be studied more in deep.
Visfatin is encoded by the NAMPT gene. Studies
on the potential influence of functional NAMPT gene
polymorphisms in the risk of cardiovascular disease of
RA were conducted. However, no significant association of
NAMPT rs9770242 and rs59744560 polymorphisms with
disease susceptibility and cardiovasculary risk in patients
with RA was observed [154].
At cartilage level, human OA chondrocytes produce
visfatin, and similar to IL-1β, visfatin is able to enhance
the synthesis of prostaglandin E2 [155]. This adipokine
also increases the expression of ADAMTS 4, ADAMTS5,
MMP-3, and MMP-13, which are very relevant cartilage
degradative enzymes [155]. To note, OA patients had higher
synovial fluid visfatin concentrations, which are correlated
with degradation biomarkers such as collagen type II and
aggrecan [156]. Taken together, these data indicate that
visfatin develops catabolic functions at cartilage level, and it
could play an important role in the pathophysiology of OA.
Studies performed in SLE and AS patients present
conflicting results. Some authors determined higher visfatin
levels in SLE patients than in healthy controls [73], but others
did not found any variation between patients and controls
[157]. Similarly, there was no association between visfatin
levels and disease activity in both SLE and AS [77, 157].
11. Resistin
Resistin, known as adipocyte-secreted factor (ADSF) or
found in inflammatory zone 3 (FIZZ3), was discovered in
2001 and was proposed as potential link between obesity and
diabetes [158]. It was secreted by adipose tissue but has been
found also in macrophages, neutrophils, and other cell types.
Serum resistin levels increase with obesity in mice, rats, and
humans [159, 160]. Resistin belongs to a family of resistin-
like molecules (RLM) with distinct expression patterns and
biological effects [161].
In animal models, resistin promotes insulin resistance,
while the evidence for this effect in human is less clear
[158, 162]. Also, it was observed that resistin production is
restricted to adipocytes in mice, while in humans it is mainly
derived from circulating monocytes and macrophages [163].
12. Resistin and Atherosclerosis
Increasing evidence indicates that resistin might play impor-
tant regulatory roles apart from its role in insulin resistance
and diabetes, in a variety of biological processes such
as atherosclerosis and cardiovascular diseases (Figure 1).
Several studies suggested that resistin was involved in
pathological processes, leading to CVD including inflam-
mation, endothelial dysfunction, thrombosis, angiogenesis,
and smooth muscle cell dysfunction [164, 165]. Several
studies have showed that CVD is accompanied by changes
in serum resistin levels, including [166]. Moreover, a sim-
ilar study demonstrated a significant increase in plasma
resistin levels in patients with unstable angina when com-
pared with patients with stable angina or control patients
[167]. Resistin levels were elevated in ACS, which has
been hypothesized to be due to release of resistin from
atherosclerotic plaque during plaque rupture [168]. In
addition, the group of Jung has showed that macrophages
infiltrating atherosclerotic aneurysms were able to secrete
resistin, which in turn, affects endothelial function and
vascular smooth muscle cell migration, thus, contributing
to atherogenesis [169]. Resistin also might be involved
in the maintenance of epithelial cell barrier function, a
physical barrier between blood and the arterial wall. In
fact, it has been reported that high concentrations of
resistin generated in conditional media from epicardial
adipose tissue of patients with ACS, increase endothelial
cell permeability [170]. Very recently, a novel role of
resitin has been described in modulating serum low-density
lipoproteins and, thereby, atherosclerotic CVDs in obese
humans [171].
13. Resistin and Rheumatic Diseases
There are several demonstrations that resistin may be
involved in the pathogenesis of RA. Increased levels of this
adipokine it have previously been observed in synovial fluid
from patients of rheumatoid arthritis (RA) compared to
patients with noninflammatory rheumatic disorders [110].
Resistin may be a significant mediator in the inflammatory
process of RA. In fact, serum resistin levels are associated
with disease activity and acute phase reactants, including C-
reactive protein and IL-1Ra antagonizing IL-1β [172, 173].
However, resistin-RTN rs1862513 polymorphism was not
found to be a genetic risk factor for both clinically evident
cardiovascular disease and subclinical atherosclerosis in a
large series of patients with RA [174].
Resistin has been found in the plasma and synovial
fluid of RA patients, and injection of resistin into mice
joints induces an arthritis-like condition, with leukocyte
infiltration of synovial tissues, hypertrophy of the synovial
layer, and pannus formation [173, 175]. Bokarewa et al.
have showed that resistin induces and is induced by several
proinflammatory cytokines, such as TNF-α or IL-6, in
peripheral blood mononuclear cells, via NF-κB pathway,
indicating that resistin can increase its own activity by a
positive feedback mechanism [175]. This group has recently
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demonstrated that resistin utilizes IGF-1R pathway in RA
synovial [176].
Increased serum resistin in patients with rheumatoid
arthritis correlated with both C-reactive protein (CRP) and
DAS28, suggesting a role of this adipokine in the patho-
genesis of rheumatoid arthritis [173]. Gonzalez-Gay et al.
have confirmed this association between laboratory markers
of inflammation, particularly CRP and resistin levels and
have showed that anti-TNF-alpha therapy results in a rapid
reduction of serum resistin levels in patients with RA [177].
Recent experimental data suggest that resistin, in the
presence of dentritic cells, might induce the expansion of
functional regulatory T cells [178].
The proinflammatory profile of resistin, together with its
association with obesity, suggests that this adipokine might
be another potential mediator that links OA with inflamma-
tion and obesity.
In addition, resistin has a role as a marker of inflam-
mation in other rheumatic diseases, such as systemic lupus
erythematous (SLE) [179]. In fact, Almehed et al. have dem-
onstrated a positive correlation between serum resistin levels,
inflammation, bone mineral density, and renal functions in
patients with SLE [180].
In a very recent study, higher serum resistin levels have
been reported in patients with AS compared to healthy sub-
jects giving clues that resistin could have also a role in the
pathogenesis of AS [181].
14. Conclusions
Adipose tissue-derived factors, called adipokines, are now
considered to play multiple and relevant roles in the body,
including a complex adipokine-mediated interaction among
white adipose tissue, cardiovascular disorders, and rheumatic
diseases. The chronic increase of the inflammatory tone is
generally associated with an increased risk for the develop-
ment of cardiovascular diseases, and the proinflammatory
environment presented in rheumatic diseases contributes to
the increase of severe cardiovascular disorders. In addition,
the inflammatory functions exerted by adipokines in certain
rheumatic diseases could explain some of their associated
cardiovascular comorbidities, suggesting a potential thera-
peutic role for these molecules.
Anyway, the main causes of abnormal fat mass accumu-
lation and adipokine dysfunction are bad nutritional and
lifestyle habits, such as overeating and physical inactivity.
Therefore, the first therapeutic approach for cardiovascular
disorders in rheumatic diseases should be the correction of
these bad habits.
In summary, modification in the lifestyle, as well as
other therapeutic interventions leading to reduce fat mass,
and its associated dysfunction might improve cardiovascular
mortality in patients with rheumatic diseases.
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